Kornimate/medical-research-clean huggingface dataset:
effects of action observation training (aot) in the achievement of urinary continence in men after robot-assisted laparoscopic prostatectomy (ralp)

Conditions: Urinary Incontinence

Summary: urinary incontinence (ui) is one of the most common side effects of radical prostatectomy (rp) and compromises men's quality of life. the first line treatment for urinary incontinence is the conservative approach of pelvic floor muscle training (pfmt) but, up to date, there seems to be no statistically significant difference in the effectiveness of several proposed physiotherapy treatments. literature highlights the importance of also adding an educational component regarding the intentional contraction of the pelvic floor muscles (a skill termed "the knack"). moreover, in some studies, carried out on a sample of women, was introduced the use of virtual reality. this increased the adherence to treatment and showed an improvement in urinary continence. in addition to virtual reality, another intervention methodology used in physiotherapy is the one of action observation training (aot) whose effectiveness has been proven both in sports and rehabilitation. however, currently the effect of this innovative type of treatment has not yet been studied in men with ui following radical prostatectomy intervention. the aim of this clinical study is to investigate the effectiveness of using aot on urinary incontinence in subjects undergoing robotic radical prostatectomy.


Eligibility criteria:
inclusion criteria: * patients who have undergone robot-assisted laparoscopic prostatectomy with post-operative iu. * objectivity of recruitment and contraction of pelvic floor musculature (pp) at manual perineal testing. exclusion criteria: * preoperative incontinence * pre-intervention radiotherapy * previous urogenital surgery beyond robot-assisted laparoscopic prostatectomy. * concomitant presence of neurological, internal or musculoskeletal diseases that may affect functional or motor recovery. * less than 5 seconds of endurance in pp contraction

Keywords: robot-assisted laparoscopic prostatectomy action observation training pelvic floor muscle training
phase ii study of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention for urea cycle disorders

Conditions: Amino Acid Metabolism, Inborn Errors

Summary: objectives: i. assess the safety and efficacy of sodium phenylbutyrate, sodium benzoate, sodium phenylacetate, and dietary intervention in patients with urea cycle disorders.

protocol outline: this protocol describes several clinical studies of pharmacologic and dietary management in patients with urea cycle disorders. patients with carbamyl phosphate synthetase and ornithine transcarbamylase deficiency are treated with a low-protein diet, essential amino acids (for neonatal onset disease), caloric supplementation, oral sodium phenylbutyrate (now approved as a prescription drug 11/97), and citrulline or arginine free base. patients with argininosuccinic acid synthetase deficiency are treated with a low-protein diet, caloric supplementation, oral sodium phenylbutyrate (now approved as a prescription drug 11/97), and arginine free base. patients with argininosuccinic aciduria (aa) are treated with a low-protein diet, caloric supplementation, and arginine free base. (discontinued 11/97) any patient who develops hyperammonemia is treated with intravenous sodium benzoate, sodium phenylbutyrate, and arginine hydrochloride; benzoate and phenylbutyrate are not given to patients with aa. if ammonium stabilizes at normal or near normal levels, intravenous medications are gradually replaced by oral medications. if there is no significant decrease in ammonium within 8 hours, patients begin hemodialysis. concurrent therapy with ondansetron, high caloric intake, and mannitol for elevated intracranial pressure is allowed. dietary and intravenous nitrogen is prohibited. (discontinued 11/97)

Eligibility criteria:
protocol entry criteria: urea cycle deficiency, i.e.: carbamyl phosphate synthetase deficiency (cpsd) ornithine transcarbamylase deficiency (otcd) argininosuccinic acid synthetase deficiency (asd) argininosuccinic aciduria (aa)

Keywords: inborn errors of metabolism rare disease urea cycle disorder
the impact of body mass index on the endometrial microbiome in ivf treatments. tampere infertility microbiome project (timp).

Conditions: Infertility, Female

Summary: this study project is an observational trial involving 90 patients suffering from male type infertility. the patients are divided in two groups (45 patients per group) based on their body mass index (bmi). .

this study (tampere infertility microbiome project, timp) aims to clarify the differences in the endometrial, vaginal and anal microbiome variety between obese and healthy-weight patients. the first group will consist of patients with the body mass index (bmi) over 30 kg/m², while the second group will include patients with a healthy weight bmi 20-25 (under 26). the samples will be collected at the time of embryo transfer and analyzed in a laboratory specialing in next-geration sequencing (ngs) techniques.

Eligibility criteria:
inclusion criteria: * patients with male infertility scheduled for ivf treatment and fresh embryo transfer * primary or secondary male-type infertility * bmi over 30 kg/m² or between 20-25 kg/m² (under 26) * patient's willingness to participate exclusion criteria: * patients with endometriosis or adenomyosis * use of antibiotics during ivf treatment or oocyte retrieval * technical diffuculties in embryo transfer or no embryos available for transfer

Keywords: microbiome microbiota obesity
therapy of acute myeloid leukemia in patients over the age of 60 : da versus mitoxantrone with intermittent arac

Conditions: Leukemia, Nonlymphocytic, Acute

Summary: single arm-studies suggest improved remission and survival rates for a protocol with mitoxantron 10mg/m2 for 3 days combined with arac 1g/m2 bid on days 1+3+5+7 compared to a conventional da 7+3 protocol (45mg/m2 daunorubicin).

randomized comparison of the two protocols.

Eligibility criteria:
inclusion criteria: * diagnosis of aml * age \>60 * no previous chemo for aml * informed consent * karnofsky \>70 exclusion criteria: * aml m3 * uncontrolled sepsis * uncontrolled hypertension * respiratory failure * heart-failure nyha iv, recent myocardial infarction * severe organ dysfunction of liver, kidneys, * hiv -infection or active hepatitis b,c

Keywords: chemotherapy elderly
a phase 2, randomized dose-ranging study to evaluate the efficacy of tralokinumab in adults with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: to study the safety and effectiveness of multiple-doses of tralokinumab on pulmonary function in adults with mild to moderate idiopathic pulmonary fibrosis (ipf). ipf is a chronic, progressive, irreversible, and usually fatal lung disease of unknown cause.

the primary objective of this study is to determine the effect of multiple doses of tralokinumab on pulmonary function in adults with mild to moderate ipf

Eligibility criteria:
key inclusion criteria: * 1) ipf diagnosis for \<= 5 years prior to visit 1 (screening). confirmation of diagnosis of ipf in accordance is required for subject inclusion 2) confirmed diagnosis of ipf by clinical characteristics, hrct and surgical lung biopsy (if required) 3)mild to moderate ipf to include all of the following at screening: 1. fvc \>= 50% predicted normal 2. partial pressure of oxygen in arterial blood (pao2) of \>= 55 mmhg on room air or 50 mmhg at high altitude (\> 1500 meters), or oxygen saturation by pulse oximetry (spo2) of \>= 90%on room air at rest 3. hemoglobin-corrected diffusion capacity for carbon monoxide (dlco) \>= 30% predicted normal 4) be able to walk \>= 100 meters unassisted key exclusion criteria: 1. a fev1/fvc ratio less than 0.70 at the time of screening (postbronchodilator) 2. the extent of emphysema on the hrct is greater than the extent of fibrosis. 3. currently listed for lung transplantation 4. use of the following medications: 1. immunosuppressive medications (eg, methotrexate, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid) within 3 months prior to visit 1 (screening). oral prednisone \<= 15 mg/day (or equivalent oral corticosteroid) is allowed for chronic use if subject was on a stable dose at least 30 days prior to visit 1 (screening) 2. pirfenidone within 4 weeks prior to visit 1 (screening) 3. n-acetylcysteine within 4 weeks prior to visit 1 (screening) 4. live attenuated vaccines within 4 weeks prior to visit 1 (screening)
effects of aging and gender-affirming hormone therapy on vascular endothelial function and metabolic profiles in transgender men

Conditions: Transgender; Gender Identity; Vascular Stiffness; Vascular Inflammation; Blood Pressure; Lipid Disorder; Appetitive Behavior

Summary: this study will examine markers of vascular endothelial function (vascular health) and metabolic profiles in older versus younger transgender men (people who were assigned female at birth but whose gender identity is male). data will also be compared to those from age group-matched transgender women and cisgender women and men.


Eligibility criteria:
inclusion criteria: * aged 18-40 years old or 50-75 years old * identify as a transgender woman * have taken testosterone for at least one year * currently taking testosterone parenterally (injections) or transdermally (patches or gels) exclusion criteria: * don't identify as a transgender man * not currently taking testosterone * have been on testosterone for less than one year * history of hysterectomy/oophorectomy * current tobacco smoker * current illicit drug use * history of prior or active estrogen-dependent neoplasms * acute liver or gallbladder disease * venous thromboembolism * hypertriglyceridemia \>500 mg/dl * fasted plasma glucose \>7.0 mmol/l or previously treated diabetes * resting blood pressure \>140/90 mmhg
evaluation of mucoadhesive tacrolimus patch on caspase-3 inducing apoptosis in oral lichen planus

Conditions: Oral Lichen Planus

Summary: tacrolimus has been widely used as an immunosuppressant. the objective of this study was to evaluate the clinical efficacy of tacrolimus 0.1 % in muco adhesive patch compared to tacrolimus or corticosteroids in paste forms for symptomatic oral lichen planus, and to investigate the effect of topical tacrolimus or corticosteroids on the expression of caspase-3 in oral lichen planus as an early marker of apoptosis using immunohistochemically analysis

thirty patients with erosive or atrophic olp were randomly assigned into three equal groups to receive topical steroid ( triamcinolone acetonide 0.1%), four times per day ( group 1), tacrolimus paste 0.1% four times per day ( group 2) , and tacrolimus patch 2 times per day ( group 3). all groups are given treatment for 8 weeks and 4 weeks follow up period without treatment. photographs of the most severe lesion were taken ( marker lesion ) in each patient and analyzed for total ulcerative area (tua), total atrophic area (taa). patients were also assessed using clinical scores (cs) and visual analogue scale (vas). pre treatment and post treatment specimens were immunohistochemically stained to detect expression of caspase-3.

Eligibility criteria:
inclusion criteria: * clinically and histologically proven painful bullous/erosive or atrophic forms of olp exclusion criteria: * lichenoid lesions smoking systemic conditions pregnancy or breast feeding known hypersnstivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation
a safety and pharmacodynamic study of healthy chinese subjects administered sodium zirconium cyclosilicate (zs)

Conditions: Hyperkalemia

Summary: this is a single center, inpatient, open label pharmacodynamic study to determine the effect of 5 g and 10 g doses of sodium zirconium cyclosilicate (zs) administered once daily (qd) for 4 days on potassium and sodium excretion in healthy chinese subjects on a standardized, low sodium and high potassium diet.

this study will be conducted at 1 study centre in hong kong. approximately 22 subjects will be screened to achieve 20 subjects completing the study. subjects will be randomized to receive zs 5 g or 10 g (1:1) once daily (qd) in conjunction with breakfast and will be continued with a standard diet during the zs treatment period.

Eligibility criteria:
key inclusion criteria: 1. provision of informed consent prior to any study specific procedures 2. female and/or male healthy chinese subjects aged between 18 and 55 inclusive who reside in hong kong 3. ability to have repeated blood draws or effective venous catheterization 4. willing to consume food and beverages using a standardized daily diet containing 40 (± 10%) meq/day sodium and 128 (± 10%) meq/day potassium provided by the research site key exclusion criteria: 1. participation in another clinical study with an investigational product during the last 3 months 2. subjects who were receiving concomitant medications including vitamins, dietary supplements and herbal preparations within 2 weeks prior to study day 1 of the diet run-in period. 3. current and/or past history of alcohol abuse within the past year or a positive results (exceed normal range) of breath test for alcohol abuse 4. current and/or past history of drugs abuse within the past year or a positive drug abuse screen, e. g. methylenedioxymethamphetamine, opiate, barbiturates, benzodiazepines, ketamine, cocaine, amphetamine, methamphetamine, marijuana, and methadone. 5. plasma donation within 1 month of screening or any blood donation/blood loss \>500 ml during the 3 months prior to screening.

Keywords: healthy chinese subjects, pharmacodynamic study
the effect of casein phosphopeptide amorphous calcium phosphate on affected dentine

Conditions: Caries,Dental

Summary: teeth selected for intervention with atraumatic restorative treatment will receive glass ionomer restorations (control) or mi varnish (test) before receiving the glass ionomer restoration

patients selected to participate in the study will be randomly assigned into 2 groups. group 1 (test): who will receive casein phosphopeptide amorphous calcium phosphate (cpp-acp) + art in the teeth selected, excavating only the caries infected dentine and preserving the caries affected dentine. group 2 (control): who will receive art only in the teeth selected, excavating only the caries infected dentine and preserving the caries affected dentine.

Eligibility criteria:
inclusion criteria: 1. healthy patients. 2. patients with an age range of 6-8 years old for clinical evaluation. 3. patients ranking definitely positive or positive on frankl scale. 4. patients having at least 1 symptomless primary molar with caries extending to the dentine (international caries detection and assessment system (icdas ii) code 4, 5 \& 6). 5. the presence of the permanent successors when examined by periapical x-ray. 6. patients who will agree to participate in the study. for the ex-vivo sample 1. patients with an age range of 9-11 years old. 2. the selected teeth should have more than half of their roots physiologically resorbed when examined by periapical x-ray. exclusion criteria: 1. patients with special health care needs (physical, mental or medical). 2. primary molars that are mobile, ankylosed or have periapical pathology on initial examination clinically and radiographically.

Keywords: casein phosphopeptide amorphous calcium phosphate cpp-acp caries affected dentine dentine repair atraumatic restorative treatment
post-exposure prophylaxis for asymptomatic sars-cov-2 covid-19 patients with choloroquine compounds

Conditions: SARS-CoV-2; Coronavirus Infection; Asymptomatic Condition; COVID-19

Summary: to create a protocol for treatment of pakistani patients with sars-cov-2 infection with an intent to reduce burden on institutional healthcare services by determining efficacy of different quinone drug dosing regimens in controlling sars-cov-2 infection for asymptomatic patients.


Eligibility criteria:
inclusion criteria: 1. nasopharyngeal rt-pcr positive sars-cov-2 patient 2. age 20-50 years 3. bmi 18-28 kg/m2 4. informed consent exclusion criteria: 1. symptoms: cough, fever, shortness of breath 2. o2 saturation by pulse-oximeter below 94% 3. co-morbidities: any pre-existing cardiac disease, pulmonary disease, diabetes 4. arrhythmias and/or history of arrythmia 5. psoriasis and/or history of psoriasis 6. neuropathy or myopathy and/or history of these 7. hypoglycemia and/or history of hypoglycemia 8. pre-existing hepatic disease 9. pre-existing renal disease 10. use of antacids within 1 week 11. use of antibiotics within 1 week 12. pregnancy 13. rt-pcr performed \>3 days prior to enrollment
comparing single- vs multi-fraction spine stereotactic radiosurgery in spinal metastases

Conditions: Spinal Metastases

Summary: the goal of this study is to determine whether fractionated stereotactic radiosurgery (srs) for spine metastases is associated with improved local tumor control compared to single-fraction srs. patients will be randomized to treatment with spine srs using either 22 gy in 1 fraction or 28 gy in 2 fractions.


Eligibility criteria:
inclusion criteria: * histologically, cytologically, or radiographically confirmed diagnosis of metastatic cancer age ≥ 18 years * patients who have cervical, thoracic, or lumbar spine metastasis that need treatment. * patients will have 1 to 3 separate spinal sites that require treatment. * each spinal site to be treated on trial will span 1-2 contiguous vertebral levels * ecog 0-2 * negative serum or urine pregnancy test within 14 days prior to enrollment for people of childbearing potential or who are not postmenopausal * people of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control * ability to understand and the willingness to sign (personally or by a legal authorized representative) the written irb approved informed consent document exclusion criteria: * prior or planned radiation off study within or overlapping with study treatment site * inability to have either an mri or a ct scan. patients with pacemaker will be allowed to undergo ct instead of mri * pediatric patients (age \<18 years old), pregnant women, and nursing patients will be excluded * histology's of myeloma or lymphoma * patients with strength 1-3 (of 5), bladder incontinence, bowel incontinence, and/or bladder retention that is associated with spinal site to be treated * prior surgery to spinal site intended to be treated with protocol srs * excluded those with sins 13-18

Keywords: spine stereotactic radiosurgery cervical lumbar thoracic metastases
impulsivity, neural deficits and cocaine addiction

Conditions: Cocaine Dependence

Summary: the purpose of this study is to assess neurocognitive and associated neural regions/circuitry disruptions relevant to impulsive relapse in cocaine-addicted subjects, and the relationship of the cognitive and neural mechanisms of impulsivity/decision-making to relapse style.

this study is designed to explore putative differences in impulsive behaviors and decision making in cocaine-addicted and healthy control subjects using functional magnetic resonance imaging (fmri), single photon emission tomography (spect), and neurocognitive tasks. we predict that cocaine-addicted subjects will demonstrate neurocognitive and neural alterations in measures of impulsivity and decision-making when compared to healthy controls. that is, cocaine-addicted subjects will show both decreased activation and decreased resting measures of regional cerebral blood flow (rcbf) of the brain structures associated with impulsivity and decision-making. furthermore, neurocognitive and neural deficits associated with impulsivity and decision-making will be associated with each other and with measures indicative of an impulsive relapse and altered decision making.

Eligibility criteria:
inclusion criteria: * cocaine-dependence (patient population) or no cocaine-dependence (control population). exclusion criteria: * other medical or psychiatric disorders that may effect neural functioning. * medications that may effect neural functioning.

Keywords: impulsivity cocaine dependence relapse neuroimaging functional magnetic resonance imaging (fmri) single photon emission computed tomography (spect)
assessing quality of life of patients with prostate cancer

Conditions: Prostate Cancer

Summary: rationale: quality of life assessment in patients undergoing prostate cancer treatment may help determine the intermediate and long-term effects of the treatment on these patients. purpose: clinical trial to study the effectiveness of two questionnaires in assessing quality of life of patients who have prostate cancer.

objectives: * assess the scale structure, psychometric validity, and reliability of quality of life measurements using the eortc qlq-c30 and the prostate cancer-specific qlq-pr25 questionnaires in patients with stage i-iv prostate cancer. outline: this is a multicenter study. patients are stratified according to stage of disease (local or locally advanced disease vs metastatic disease). patients complete eortc qlq-c30 and prostate cancer-specific qlq-pr25 questionnaires before therapy and at 3 months after the start of therapy. patients in stratum ii also complete questionnaires at 6 months after the start of therapy. projected accrual: a total of 375 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed prostate cancer * stratum i: * clinically localized primary prostate cancer * t1-t3, g1-g3, n0, m0 * plan to undergo a radical prostatectomy or * local or locally advanced primary prostate cancer * t1-t4, g1-g3, n0, m0 * plan to undergo radiotherapy with curative intent * stratum ii: * metastatic prostate cancer * t1-t4, g1-g3, n1, m0-m1 or * t1-t4, g1-g3, n0-1, m1 * plan to receive hormonal treatment * no anti-androgen monotherapy * no cerebral metastases patient characteristics: age: * any age performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * mentally fit to complete a questionnaire * literate in the language of the questionnaires * no psychological, familial, sociological, or geographical condition that would preclude compliance * no other concurrent malignancy except basal cell skin cancer * no concurrent participation in other quality of life investigations that would preclude study participation prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * see disease characteristics * no prior neoadjuvant hormonal treatment * planned adjuvant hormonal therapy (orchiectomy, luteinizing hormone-releasing hormone analogue, or maximal androgen blockade) is allowed for patients in stratum i radiotherapy: * see disease characteristics * no interstitial radiotherapy * more than 2 years since prior radiotherapy (stratum ii) surgery: * see disease characteristics * more than 2 years since prior prostatectomy (stratum ii) other: * no prior treatment for prostate carcinoma

Keywords: stage i prostate cancer stage iib prostate cancer stage iia prostate cancer stage iii prostate cancer stage iv prostate cancer